Clinical Trials Logo

Filter by:
  • Suspended  
  • Page [1] ·  Next »
NCT ID: NCT06298669 Suspended - Heart Failure Clinical Trials

Biventricular Versus Right Ventricular Pacing

Start date: August 9, 2023
Phase: N/A
Study type: Interventional

The study is a randomized, single-blind crossover prospective study in which investigators will determine the clinical outcomes of cardiac resynchronization therapy (CRT) pacing modalities in patients with left ventricular assist devices (LVAD). Only patients are blinded. This is a small-scale study from which future larger scale randomized controls can be performed. The primary endpoint will be the effect of BiV and RV pacing setting on the 6-minute walk test.

NCT ID: NCT06210945 Suspended - Systemic Sclerosis Clinical Trials

Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

ABATE
Start date: September 2024
Phase: Phase 2
Study type: Interventional

This study is designed to assess the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with systemic sclerosis (SSc). Approximately 45 patients at approximately 40 sites will be randomized in a 2:1 ratio to receive either 10 mg/kg CM-101 or placebo.

NCT ID: NCT06160700 Suspended - Cancer Clinical Trials

Serial Testing To Assess Cognitive Function In Cancer

Start date: April 20, 2022
Phase:
Study type: Observational

The purpose of this study is to examine the effects of immunotherapy on cognitive function of cancer patients and follow them clinically over a period of six months with the Montreal cognitive assessment (MoCA) to assess changes in cognition.

NCT ID: NCT06124118 Suspended - Clinical trials for Non Small Cell Lung Cancer

Tumor Treating Fields for Locally Advanced NSCLC

NOVOCURE
Start date: November 3, 2023
Phase: Phase 1
Study type: Interventional

The goal of this open-label, Phase 1 clinical trial is to determine the safety of TTFields started concurrently with SOC chemoradiation and during consolidation durvalumab in locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). The main question it aims to answer is, "What is the rate of dose-limiting toxicities (DLTs) with TTFields in addition to concurrent chemoradiation and consolidation durvalumab?" Step 1 - All participants will be screened and enrolled in Step 1 prior to SOC concurrent chemoradiation. - The purpose of the Step 1 Registration is to ensure that eligible participants are candidate for concurrent chemoradiation and do not have contraindications to TTF therapy or immunotherapy. - Starting Level: Participants in Device Duration Level 1 will receive standard of care concurrent chemoradiation following Step 1 Registration. - Escalation Level : Participants in Device Duration Level 2 will begin standard of care chemoradiation and treatment with TTFields following Step 1 Registration. Step 2 - All participants will complete Step 2 screening and enrollment prior to receiving treatment with durvalumab consolidation therapy and TTFields. - The purpose of the Step 2 registration is to ensure that eligible patients meet criteria for consolidation durvalumab after completion of CRT and do not have contraindications to TTF. therapy or immunotherapy.

NCT ID: NCT06113289 Suspended - Clinical trials for Acute Myeloid Leukemia

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Start date: February 8, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To find the recommended dose of the study drugs ASTX727 and ASTX029 that can be given to patients with relapsed/refractory AML. The goal of Part 2 of the study is to learn if the dose of study drugs found in Part 1B can help to control AML.

NCT ID: NCT06076525 Suspended - Falling Clinical Trials

Motor Flexibility in Multidirectional Balance Control

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this observational study is to learn about how older adults (those 65 and above) manage to maintain balance when experiencing a slip or trip while walking. The study is especially interested in how quickly and flexibly adjustments to movement can be made to avoid falling. The main questions this study aims to answer are: - How does the ability to adjust movements quickly, also known as "motor flexibility," affect the chances of recovering from a slip or trip? - Can targeted training improve this ability in older adults, making falls less likely? Participants will walk on a specially designed treadmill that can simulate slips and trips and undergo a training program designed to improve the ability to adjust movements quickly. Researchers will compare older adults to younger adults to see if age affects the ability to adjust movements quickly and recover balance after a slip or trip. Researcher's will also compare the performance of older adults before and after the training program to see if balance recovery improves.

NCT ID: NCT06055556 Suspended - Clinical trials for Congenital Heart Disease

Partial Heart Transplantation

Start date: August 4, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a partial heart transplantation in patients with congenital heart disease is safe and feasible. Participants will have a partial heart transplant involving surgical replacement of the pulmonary valve with the heart valve and supporting blood vessels from an organ donor. The procedure, tests, medications, and follow-up visits will all be done per standard of care. Medical data will be collected to look at outcomes after surgery.

NCT ID: NCT06046482 Suspended - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Start date: November 28, 2023
Phase: Phase 2
Study type: Interventional

To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs. The safety of magrolimab will also be studied.

NCT ID: NCT05998785 Suspended - Clinical trials for Insertional Achilles Tendinopathy

Embody Insertional Achilles Tendinopathy

IAT
Start date: August 2, 2022
Phase:
Study type: Observational

The primary objective of this study is to evaluate the long-term effects on ankle/Achilles tendon pain after repair of insertional Achilles tendinopathy (IAT) augmented with TAPESTRY Biointegrative Implant.

NCT ID: NCT05950399 Suspended - Clinical trials for Malignant Solid Neoplasm

Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk

Start date: June 29, 2015
Phase: N/A
Study type: Interventional

This clinical trial evaluates changes in cardiac (heart) function during stress echocardiography to screen for chemically induced cardiotoxicity in cancer patients at a high risk for developing heart failure. Some chemotherapeutic agents to treat certain types of cancers can induce cardiac dysfunction and heart failure. Currently there is no validated means of predicting which patients will go on to develop cardiac toxicity and heart failure following treatment with chemotherapeutic agents. Stress echocardiography is a test that uses ultrasound imaging to show how well the heart muscle is working to pump blood to the body during low intensity exercise. Stress echocardiography prior to and during cancer treatment may help doctors find cancer therapeutic related cardiac dysfunction sooner when it may be easier to treat.